Quest Partners LLC Purchases 14,914 Shares of Hologic, Inc. (NASDAQ:HOLX)

Quest Partners LLC raised its holdings in Hologic, Inc. (NASDAQ:HOLX) by 56.1% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 41,492 shares of the medical equipment provider’s stock after acquiring an additional 14,914 shares during the quarter. Hologic comprises approximately 0.4% of Quest Partners LLC’s holdings, making the stock its 9th largest position. Quest Partners LLC’s holdings in Hologic were worth $3,081,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the business. Innealta Capital LLC acquired a new position in shares of Hologic during the 2nd quarter valued at about $25,000. iA Global Asset Management Inc. acquired a new position in Hologic during the first quarter valued at approximately $37,000. Mather Group LLC. bought a new position in shares of Hologic in the first quarter valued at approximately $48,000. Massmutual Trust Co. FSB ADV lifted its stake in shares of Hologic by 24.7% in the first quarter. Massmutual Trust Co. FSB ADV now owns 691 shares of the medical equipment provider’s stock worth $54,000 after buying an additional 137 shares during the last quarter. Finally, Toth Financial Advisory Corp boosted its holdings in shares of Hologic by 81.1% during the 1st quarter. Toth Financial Advisory Corp now owns 775 shares of the medical equipment provider’s stock worth $60,000 after buying an additional 347 shares during the period. 94.73% of the stock is owned by institutional investors.

Hologic Trading Up 0.7 %

Shares of Hologic stock opened at $81.57 on Monday. The company’s fifty day moving average price is $79.45 and its two-hundred day moving average price is $76.65. The firm has a market capitalization of $18.95 billion, a PE ratio of 41.62, a price-to-earnings-growth ratio of 2.58 and a beta of 0.98. Hologic, Inc. has a 52-week low of $64.02 and a 52-week high of $84.67. The company has a debt-to-equity ratio of 0.51, a current ratio of 3.99 and a quick ratio of 3.32.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Monday, July 29th. The medical equipment provider reported $1.06 EPS for the quarter, topping analysts’ consensus estimates of $1.02 by $0.04. Hologic had a net margin of 17.59% and a return on equity of 19.53%. The firm had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $1 billion. During the same quarter last year, the company earned $0.93 earnings per share. The company’s revenue for the quarter was up 2.7% compared to the same quarter last year. On average, analysts expect that Hologic, Inc. will post 4.09 EPS for the current year.

Wall Street Analyst Weigh In

HOLX has been the topic of several recent analyst reports. Stephens reiterated an “overweight” rating and issued a $92.00 target price on shares of Hologic in a report on Tuesday, July 30th. JPMorgan Chase & Co. lifted their price objective on Hologic from $91.00 to $95.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 30th. Needham & Company LLC restated a “buy” rating and set a $90.00 target price on shares of Hologic in a research note on Tuesday, July 30th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $82.00 price target on shares of Hologic in a research report on Friday, August 16th. Finally, StockNews.com lowered Hologic from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 10th. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, Hologic has a consensus rating of “Moderate Buy” and an average target price of $87.60.

Insider Activity at Hologic

In other Hologic news, insider Benjamin Jordan Cohn sold 5,093 shares of the stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $81.99, for a total transaction of $417,575.07. Following the completion of the transaction, the insider now directly owns 10,476 shares in the company, valued at $858,927.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Hologic news, insider Benjamin Jordan Cohn sold 5,093 shares of the company’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $81.99, for a total transaction of $417,575.07. Following the sale, the insider now directly owns 10,476 shares of the company’s stock, valued at $858,927.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Christiana Stamoulis sold 9,039 shares of Hologic stock in a transaction that occurred on Wednesday, July 17th. The shares were sold at an average price of $79.50, for a total transaction of $718,600.50. Following the completion of the transaction, the director now owns 45,472 shares of the company’s stock, valued at approximately $3,615,024. The disclosure for this sale can be found here. Insiders have sold a total of 18,280 shares of company stock valued at $1,469,973 in the last 90 days. 1.75% of the stock is owned by corporate insiders.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.